07:50 AM EST, 11/24/2025 (MT Newswires) -- CureVac ( CVAC ) reported Q3 earnings Monday of 1.21 euros ($1.40) per diluted share, down from 1.50 euros a year earlier.

Revenue for the quarter ended Sept. 30 was 54.1 million euros, down from 493.9 million euros a year earlier.

Two analysts polled by FactSet expected 21.4 million euros.

The decline in revenue was primarily driven by the absence of a one-time revenue of 480.4 million euros recognized in Q3 2024 in connection with the new license agreement with GlaxoSmithKline Biologicals.

As of Sept. 30, the company said it had 416.1 million euros in cash and cash equivalents. It also reaffirmed its expected cash runway into 2028.